Showing results (941-950 of 2,567) with videos related to
Sort By:
Pageof 257
Frontiers in Genome Editing|October 14, 2022
In vivo and in vitro genome editing to explore GNE functionsNili Ilouz, Avi Harazi, Miriam Guttman, et al.Cells|June 2, 2021
In Vitro Fertilisation of Mouse Oocytes in L-Proline and L-Pipecolic Acid Improves Subsequent DevelopmentTamara Treleaven, Madeleine L M Hardy, Michelle Guttman-Jones, et al.CNS Drugs|May 17, 2018
The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography StudyRobert Zivadinov, Eleonora Tavazzi, Jesper Hagemeier, et al.Journal of the Neurological Sciences|April 11, 2003
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patientsLinh T Nguyen, Murali Ramanathan, Bianca Weinstock-Guttman, et al.The Journal of Allergy and Clinical Immunology. in Practice|March 9, 2021
Biologics for Treatment of Atopic Dermatitis: Current Status and Future ProspectThanaporn Ratchataswan, Tina M Banzon, Jacob P Thyssen, et al.Dermatology and Therapy|September 6, 2025
Rocatinlimab: A Novel T-Cell Rebalancing Therapy Targeting the OX40 Receptor in Atopic DermatitisEmma Guttman-Yassky, Eric Simpson, Ehsanollah Esfandiari, et al.Movement Disorders : Official Journal of the Movement Disorder Society|September 23, 2003
Nigral glutathione deficiency is not specific for idiopathic Parkinson's diseasePaul S Fitzmaurice, Lee Ang, Mark Guttman, et al.Electrophoresis|May 19, 2001
Genotyping the -521C/T functional polymorphism in the promoter region of dopamine D4 receptor (DRD4) geneZ Ronai, C Barta, A Guttman, et al.Elife|October 2, 2019
Interplay of disordered and ordered regions of a human small heat shock protein yields an ensemble of 'quasi-ordered' statesAmanda F Clouser, Hannah Er Baughman, Benjamin Basanta, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 9, 2011
Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1aD M Miller, B Weinstock-Guttman, D Bourdette, et al.Pageof 257